CSBR · Champions Oncology, Inc.
$5.26
-0.20 (-3.66%)
At close · Jul 30
Market Cap
$73.08M
Shares
13.89M
Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.
Revenue
$59.43M
+4.4%
FY2026
Net Income
-$1.18M
-125%
FY2026
Gross Margin
48%
-2.2pp
FY2026
Operating Margin
-1.92%
-9.9pp
FY2026
Diluted EPS
-$0.08
-124.2%
FY2026
Operating Cash Flow
-$4.47M
-160.5%
FY2026
Chart any reported metric, KPI or segment over time — the full statement history lives here
Search above to add metrics — fundamentals, product and segment revenue, company KPIs, valuation.
| Line Item | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 | FY2014 | FY2013 | FY2012 | FY2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| $59.43M | $56.94M | $50.16M | $53.87M | $49.11M | $41.04M | $32.12M | $2.9M | $20.24M | — | — | — | — | — | — | — | |
| $30.9M | $28.39M | $29.4M | $29.53M | $23.63M | $21.45M | $17M | — | — | — | — | — | — | — | — | — | |
| $28.53M | $28.56M | $20.75M | $24.34M | $25.48M | $19.59M | $15.12M | — | — | — | — | — | — | — | — | — | |
| 48% | 50.15% | 41.38% | 45.18% | 51.88% | 47.74% | 47.08% | — | — | — | — | — | — | — | — | — | |
| $9.08M | $6.83M | $9.54M | $11.55M | $9.37M | $7.2M | $5.85M | $4.8M | $4.4M | $4.29M | $4.19M | $4.85M | $2.27M | $1.92M | $2.94M | $2.91M | |
| $9.32M | $7.55M | $7.06M | $7M | $6.38M | $5.52M | $4.24M | $3.06M | $2.57M | $3.26M | $3.45M | $4.28M | $3.16M | $2.67M | $2.93M | $1.09M | |
| $11.15M | $9.34M | $11.07M | $10.24M | $9.12M | $6.51M | $6.61M | $4.68M | $4.07M | $4.96M | $5.17M | $5.34M | $6.13M | $4.63M | $5.45M | $4.61M | |
| $1.4M | $1.6M | $1.9M | $2.1M | $1.5M | $925K | $825K | $606K | $360K | $168K | $156K | $214K | $213K | $203K | — | — | |
| — | — | — | — | — | — | $33.93M | $26.8M | $21.6M | $22.22M | $21.5M | $22.1M | $17.81M | $14.54M | $16.21M | $12.12M | |
| -$1.14M | $4.55M | -$7.36M | -$5.26M | $607K | $366K | -$1.92M | $270K | -$1.35M | -$6.81M | -$10.32M | -$13.24M | -$6.26M | -$6.22M | -$9.07M | -$5.24M | |
| -1.92% | 8% | -14.67% | -9.76% | 1.24% | 0.89% | -5.98% | 9.31% | -6.69% | — | — | — | — | — | — | — | |
| $260K | $6.15M | -$5.46M | -$3.16M | $2.11M | $1.29M | -$1.1M | $876K | -$994K | -$6.64M | -$10.16M | -$13.02M | -$6.05M | -$6.02M | — | — | |
| $211K | $73K | $48K | -$11K | -$24K | $71K | -$42K | -$39K | -$89K | -$56K | -$38K | $225K | -$1.13M | -$99K | $402K | $1.44M | |
| -$929K | $4.63M | -$7.31M | -$5.27M | $583K | $437K | -$1.96M | $231K | -$1.44M | -$6.87M | -$10.35M | -$13.01M | -$7.39M | -$6.32M | -$8.66M | -$3.79M | |
| $246K | -$75K | -$32K | $68K | $35K | $75K | $130K | $103K | $33K | $19K | $92K | $127K | $17K | $10K | -$2000 | $11K | |
| -$1.18M | $4.7M | -$7.28M | -$5.34M | $548K | $362K | -$2.09M | $128K | -$1.48M | -$6.88M | -$10.45M | -$13.14M | -$7.41M | -$6.33M | -$8.66M | -$3.8M | |
| -1.98% | 8.26% | -14.51% | -9.9% | 1.12% | 0.88% | -6.52% | 4.41% | -7.29% | — | — | — | — | — | — | — | |
| — | — | — | — | — | — | — | — | — | — | — | -$13.14M | -$7.31M | -$6.31M | -$8.72M | -$3.87M | |
| USD/shares | -$0.08 | $0.34 | -$0.54 | -$0.39 | $0.04 | $0.03 | -$0.18 | $0.01 | -$0.13 | — | -$1.20 | -$2.20 | -$0.11 | — | — | — |
| USD/shares | -$0.08 | $0.33 | -$0.54 | -$0.39 | $0.04 | $0.02 | -$0.18 | $0.01 | -$0.13 | — | -$1.20 | -$2.20 | -$0.11 | — | — | — |
| shares | 13.83M | 13.66M | 13.55M | 13.54M | 13.2M | 13.14M | 11.84M | 11.34M | 10.99M | 10.68M | 8.7M | 5.99M | 66.86M | 52.05M | 46.82M | — |
| shares | 13.83M | 14.27M | 13.55M | 13.54M | 14.16M | 14.57M | 11.84M | 14.1M | 10.99M | 10.68M | 8.7M | 6.42M | 66.86M | 52.05M | 46.82M | — |
Italic rows are computed from reported lines — open a row's info icon for its formula. Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing.
3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative.
Capital Returned to Shareholders
Cash spent on share repurchases and dividends per fiscal year, as reported on the cash-flow statement. Across FY2011–FY2025: $1.74M in buybacks.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against peers, and each ratio recomputed as of past filing dates.
Valuation
EV/Revenue
—
Peer median 4.22×
EV/EBIT
—
Peer median 49.60×
P/E (TTM)
—
Peer median 2.80×
Peer medians compare against the 292 similar-size Biotechnology companies (of 522 listed).
Valuation over time computed as of each quarter's filing date
Revenue Breakdown
Annual revenue as the company disaggregates it in its own XBRL filings. Years a component wasn't reported show a dash.
Share mode is each component's slice of the reported components that year — issuers rarely tag every revenue dollar, so slices need not sum to total revenue.
By Product & Service (USD)
| Component | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|---|
| Pharmacology Services | $57,133,000 | $48,585,000 | $47,035,000 | $50,708,000 | $46,833,000 | $39,473,000 | $31,262,000 |
| Product And Service Other | $1,528,000 | $3,683,000 | $3,102,000 | $3,046,000 | — | — | — |
| Translational Oncology Solutions TOS License Revenue | $764,000 | $4,676,000 | — | — | — | — | — |
| Other Services | — | — | — | — | $2,227,000 | $1,401,000 | $71,000 |
| Personalized Oncology Services | — | — | $18,000 | $116,000 | $49,000 | $166,000 | $790,000 |
| License And Maintenance | — | — | $0 | — | — | — | — |